Johnson & Johnson wins full FDA approval for bladder cancer therapy Balversa

Johnson & Johnson (NYSE:JNJ) on Friday received full FDA approval for its bladder cancer therapy erdafitinib (Balversa) as a late-line option for certain patients with urothelial carcinoma.